Amylyx Pharmaceuticals (AMLX) Invested Capital: 2021-2025
Historic Invested Capital for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $332.0 million.
- Amylyx Pharmaceuticals' Invested Capital rose 69.21% to $332.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.0 million, marking a year-over-year increase of 69.21%. This contributed to the annual value of $164.8 million for FY2024, which is 61.99% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Invested Capital stood at $332.0 million, which was up 97.76% from $167.9 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' 5-year Invested Capital high stood at $433.4 million for Q4 2023, and its period low was -$151.2 million during Q4 2021.
- Over the past 3 years, Amylyx Pharmaceuticals' median Invested Capital value was $324.4 million (recorded in 2024), while the average stood at $294.4 million.
- Its Invested Capital has fluctuated over the past 5 years, first surged by 325.32% in 2022, then tumbled by 61.99% in 2024.
- Over the past 5 years, Amylyx Pharmaceuticals' Invested Capital (Quarterly) stood at -$151.2 million in 2021, then soared by 325.32% to $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then plummeted by 61.99% to $164.8 million in 2024, then soared by 69.21% to $332.0 million in 2025.
- Its Invested Capital was $332.0 million in Q3 2025, compared to $167.9 million in Q2 2025 and $201.4 million in Q1 2025.